SCHEMBL754977

SCHEMBL754977

COC(=O)c1ccc(Oc2ccc([C@H](C)[C@](O)(c3cc(C)c(=O)n(C)c3)C(F)(F)F)c(Cl)c2)cc1Cl

nearest known ligand 0.32

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.32
CYP2C19 P33261 1/20 0.32
BRD4 O60885 2/20 0.32
LMNA P02545 2/20 0.32
GAA P10253 1/20 0.32
PDK2 Q15119 1/20 0.31
PDE2A O00408 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
ATM Q13315 1/20 0.31
BAZ2B Q9UIF8 1/20 0.31
BAZ2A Q9UIF9 1/20 0.31
P2RX3 P56373 1/20 0.31
PPARG P37231 1/20 0.30
PPARD Q03181 1/20 0.30
PPARA Q07869 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480703 1.00 CYP1A2 (0.32) CYP1A2CYP2C19BRD4LMNAGAA
SCHEMBL755669 0.94 P2RX3 (0.35) BRD4LMNAGAAPDE2AMAPT
SCHEMBL480608 0.94 P2RX3 (0.35) BRD4LMNAGAAPDE2AMAPT
SCHEMBL755679 0.94 LMNA (0.34) CYP1A2CYP2C19BRD4LMNAGAA
SCHEMBL480071 0.94 LMNA (0.34) CYP1A2CYP2C19BRD4LMNAGAA
SCHEMBL753353 0.91 S1PR2 (0.34) BRD4KMT2APPARGPPARDPPARA
SCHEMBL480687 0.91 S1PR2 (0.34) BRD4KMT2APPARGPPARDPPARA
SCHEMBL480093 0.89 SCN8A (0.34) CYP1A2CYP2C19LMNAGAAPDK2
SCHEMBL753039 0.89 SCN8A (0.34) CYP1A2CYP2C19LMNAGAAPDK2
SCHEMBL480726 0.87 P2RX3 (0.33) BRD4P2RX3PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 CYP1A2 209/4885CYP2C19 330/4885BRD4 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.